RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Polycythaemia Vera: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Rusfertide for Polycythemia Vera: Incremental Benefit Assessment.
Tefferi Ayalew et al., American journal of hematology (17 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42891571/
- 2.
Cancer Worry and Supportive Care Needs in Patients with Polycythemia Vera: A Single-center Cross-sectional Study
Naime Kaçar Koca et al., Acta haematologica oncologica Turcica. (16 October 2026)
https://doi.org/10.4274/ahot.galenos.2026.2025-11-6
- 3.
The Hyperviscous Heart: Reversible Cardiomyopathy in Polycythemia Vera.
Arroyo-Rodríguez Cuitláhuac et al., European heart journal. Cardiovascular Imaging (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42885859/
- 4.
Beyond Phlebotomy: Iron Homeostasis in the Next Phase of Polycythemia Vera Management.
Torre Elena et al., Journal of clinical oncology : official journal of the American Society of Clinical Oncology (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42886882/
- 5.
VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy.
Kuykendall Andrew T et al., Journal of clinical oncology : official journal of the American Society of Clinical Oncology (13 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42868322/
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
NCT07429266 · Recruiting · Phase 3 · Ono Pharmaceutical Co., Ltd.
Ages 18 and over
https://clinicaltrials.gov/study/NCT07429266
- 2.
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
NCT07469891 · Recruiting · Phase 1 · Prelude Therapeutics Incorporated
Ages 18 and over
https://clinicaltrials.gov/study/NCT07469891
- 3.
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
NCT06351631 · Recruiting · Phase 3 · Merck Sharp & Dohme LLC
Ages 18 and over
https://clinicaltrials.gov/study/NCT06351631
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Polycythaemia Vera
Polycythaemia Vera is a myeloproliferative neoplasm in which the bone marrow overproduces red blood cells, causing blood thickening and increased clotting risk. It is almost universally driven by the JAK2 V617F mutation. Management includes phlebotomy, aspirin, and cytoreductive therapy with hydroxyurea or ruxolitinib. The primary risk is thrombosis and transformation to myelofibrosis.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Rusfertide mechanism of action and clinical trial results in polycythemia vera.
Common Questions
What is Polycythaemia Vera?
Polycythaemia Vera is a myeloproliferative neoplasm in which the bone marrow overproduces red blood cells, causing blood thickening and increased clotting risk. It is almost universally driven by the JAK2 V617F mutation. Management includes phlebotomy, aspirin, and cytoreductive therapy with hydroxyurea or ruxolitinib. The primary risk is thrombosis and transformation to myelofibrosis.
How many clinical trials are available for Polycythaemia Vera?
RareWays currently indexes 185 clinical trials for Polycythaemia Vera, of which 27 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Polycythaemia Vera come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Polycythaemia Vera.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.